Not all hematology patients have the same risk:Targeted approaches?

High: ᡇ%

Allo-BMT/PBSCT

Age ᡠ

Non-CML

Graft failure

Steroids

GVHD (II-IV)

Summer

No LAF ?

AML

Age ᡯ

Poor performance

High dose Ara-C

Fludarabine

Moderate: 5-10/15%

Allo-BMT/PBSCT

Age 19-40

Mismatch

Matched unrelated

Construction

Fail

AML

low: 1-5%

Allo-BMT/PBSCT

Age ឃ

CML, chronic phase

Auto-PBSCT (BMT)

Steroids (HD)

Chemotherapy (HD)

Previous slide

Next slide

Back to first slide

View graphic version